Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11464595 | 0.93 | MAPK1 (0.55) | TDP1MAPK1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL18425442 | 0.83 | ACP3 (0.51) | TDP1MAPK1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL9318733 | 0.82 | CA1 (0.58) | TDP1MAPK1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL2277677 | 0.82 | CA1 (0.58) | TDP1MAPK1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL28734391 | 0.82 | TSHR (0.38) | TDP1MAPK1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL11602455 | 0.81 | MAPK1 (0.52) | TDP1MAPK1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL2865480 | 0.81 | ADRB2 (0.41) | TDP1MAPK1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL23255698 | 0.81 | ABCB11 (0.61) | TDP1L3MBTL1TSHRCYP1A2MAPT | |
| SCHEMBL38666256 | 0.81 | ABCB11 (0.61) | TDP1L3MBTL1TSHRCYP1A2MAPT | |
| SCHEMBL6446840 | 0.81 | ABCB11 (0.61) | TDP1L3MBTL1TSHRCYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0338852-B1 | Process for the carbonylation of arylalkyl halides | HOECHST CELANESE CORP (US) | 1994-11-30 | — | — | EP | claimed |
| EP-0338852-A1 | Process for the carbonylation of arylalkyl halides | HOECHST CELANESE CORPORATION (US) | 1989-10-25 | — | — | EP | claimed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-117603074-A | Synthesis method of 2-amino-3-phenyl-2-methylbutanoic acid compound | 马鞍山诺恩特医药科技有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-1675253-A | Method for producing living radical polymer and polymer | OTSUKA CHEMICAL CO LTD (JP) | 2005-09-28 | — | — | CN | disclosed |
| CN-1649838-A | Organic tellurium compound, method for producing same, living radical polymerization initiator, method for producing polymer using same, and polymer | OTSUKA KAGAKU KK (JP) | 2005-08-03 | — | — | CN | disclosed |
| EP-1541550-A1 | ORGANIC TELLURIUM COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER WITH THE SAME, AND POLYMER | Otsuka Chemical Co., Ltd. (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1541592-A1 | PROCESS FOR PRODUCTION OF LIVING RADICAL POLYMERS AND POLYMERS | OTSUKA CHEMICAL COMPANY, LIMITED (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6555704-B1 | Preparation of alpha-aryl-propionic acids such as ibuprofen by carbonylating the corresponding 1-arylethyl halide in an acidic aqueous medium containing a phosphine/palladium catalyst; catalyst selectivity; efficiency | BASF CORPORATION | 2003-04-29 | — | — | US | disclosed |
| EP-0338852-B1 | Process for the carbonylation of arylalkyl halides | HOECHST CELANESE CORP (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5077301-A | 4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDYLPHENYLALKANE DERIVATIVES AS ANTIHISTAMINES AND METHODS OF TREATMENT OF AN ALLERGIC RESPONSE | SCHAPER & BRUEMMER GMBH & CO. KG (DE) | 1991-12-31 | — | — | US | disclosed |
| EP-0338852-A1 | Process for the carbonylation of arylalkyl halides | HOECHST CELANESE CORPORATION (US) | 1989-10-25 | — | — | EP | disclosed |
| US-4058566-A | Separation of isomers of phenols and phenolic ethers | UOP INC. (US) | 1977-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | TDP1 798/4885MAPK1 1675/4885ALDH1A1 2427/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | TDP1 1024/4885MAPK1 2088/4885ALDH1A1 2646/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | TDP1 761/4885MAPK1 1518/4885ALDH1A1 2642/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | TDP1 798/4885MAPK1 1675/4885ALDH1A1 2427/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | TDP1 798/4885MAPK1 1675/4885ALDH1A1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.